- Details
- Alicia Morgans speaks with Louise Emmett about the use of radiopharmaceuticals in prostate cancer, particularly for frail patients. Professor Emmett focuses on dosing radioligand therapy in special situations and managing toxicity, particularly marrow and kidney toxicity. She highlights the need for individualized dosing strategies, noting that current protocols might not adequately treat high-vol...
|
- Details
- Alicia Morgans interviews Ian Davis to discuss the challenges of sequencing treatments for patients with metastatic hormone-sensitive prostate cancer (mHSPC) that have progressed to metastatic castrate-resistant disease (mCRPC). Dr. Davis emphasizes that there is no ideal sequence of treatments but identifies several less-than-ideal approaches. He highlights the importance of achieving maximum ben...
|
- Details
- Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer. This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Matthew Abramowitz, MD, Associate Professor, Department of Radiation Oncology, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL Rana McKay, MD , Medical Oncologist, Associate Profe...
|
- Details
- Rashid Sayyid discusses a systematic review and meta-analysis on combining PARP inhibitors with AR signaling inhibitors in mCRPC treatment, published in BJU International. The study, which synthesized data from three significant trials, sought to improve survival across all patients, focusing on those without specific biomarkers. Results showed a 35% reduction in radiographic progression-free surv...
|
- Details
- Alicia Morgans interviews Alan Bryce about his session on radiopharmaceutical therapies for mCRPC with bone metastases, focusing on the decision-making between radium-223 and lutetium-177. Dr. Bryce explains the session aimed at practical clinical decision-making, emphasizing the underlying science of radiopharmaceuticals, including the distinctions between alpha and beta emitters and their target...
|
- Details
- Alicia Morgans interviews Maha Hussain about the BRCAAWAY trial, a phase two study exploring the efficacy of combining abiraterone and olaparib for patients with metastatic castration-resistant prostate cancer harboring BRCA1, BRCA2, or ATM mutations. Highlighting the journey from the inception of the trial to its execution, Hussain delves into the rigorous selection criteria and the strategic des...
|
- Details
- Alicia Morgans interviews Neeraj Agarwal about the CONTACT-02 trial, a phase III study that explores the combination of cabozantinib and atezolizumab in patients with metastatic castrate-resistant prostate cancer (mCRPC) who have progressed on one novel hormonal therapy (NHT). This trial, which focuses on patients with extrapelvic soft tissue metastasis, has shown a significant reduction in the ri...
|
- Details
- Daniel George hosts Michael Morris to discuss pivotal studies influencing the use of Pluvicto (lutetium PSMA-617) in treating prostate cancer. The conversation begins with the VISION study, which led to Pluvicto's approval by demonstrating significant improvements in radiographic progression-free survival (rPFS) and overall survival (OS) for patients with PSMA-positive disease. Dr. Morris outlines...
|
- Details
- At the 2024 UCSF-UCLA PSMA Conference, Matthew Rettig discusses the critical advancements and challenges in treating metastatic castration-resistant prostate cancer (mCRPC), highlighting the shift towards precision oncology with FDA-approved treatments like PARP inhibitors and Lutetium PSMA therapy, tailored to genetic mutations and PSMA PET imaging findings. Dr. Rettig emphasizes the importance o...
|
- Details
- At the 2024 UCSF-UCLA PSMA Conference, Michael Morris reviews the VISION and TheraP trials, underscoring their significance in advancing PSMA PET imaging and radioligand therapy for prostate cancer, particularly highlighting lutetium PSMA-617's efficacy in improving survival and quality of life as shown in the VISION trial. Dr. Morris stresses the importance of further research to refine patient s...
|
